Zonisamide in West syndrome.
Zonisamide (ZNS), a new antiepileptic drug developed in Japan, is being used as the initial treatment of West syndrome in some Japanese institutes. The reported response rate varied from 20 to 38%. The cryptogenic patients showed a better response than the symptomatic patients. A striking finding was that the response to ZNS is rapid; most of the children who responded did so within 1-2 weeks of starting ZNS at a dose of 4-8 mg/kg/day. No serious side effects have been reported so far. ZNS may be both effective and well tolerated for the initial treatment of selected patients with West syndrome.
Suzuki
Y
Y
Collaborate Clinical Research Group for Pediatric Neurology, Osaka University Medical School, Osaka, Japan. yasuzuki@mch.pref.osaka.jp
D000927:Anticonvulsants / Q000627:therapeutic use*; D004569:Electroencephalography; D006801:Humans; D007223:Infant; D007555:Isoxazoles / Q000627:therapeutic use*; D013036:Spasms, Infantile / Q000175:diagnosis / Q000188:drug therapy*; D000078305:Zonisamide
D000927:Anticonvulsants; D007555:Isoxazoles; D000078305:Zonisamide